Idiosyncratic drug hepatotoxicity
The DOI matches its Crossref record; 154 of the 155 references it cites were found in a registry or an index.
Abstract
The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of clinical drug development and the most frequent cause of post-marketing warnings and withdrawals. This review examines the clinical signatures of this problem, signals predictive of its occurrence (particularly of more frequent, reversible, low-grade injury) and the role of monitoring in prevention by examining several recent examples (for example, troglitazone). In addition, the failure of preclinical toxicology to predict idiosyncratic reactions, and what can be done to improve this problem, is discussed. Finally, our current understanding of the pathophysiology of experimental drug hepatotoxicity is examined, focusing on acetaminophen, particularly with respect to the role of the innate immune system and control of cell-death pathways, which might provide targets for exploration and identification of risk factors and mechanisms in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current drug development process suffers from a high failure rate during clinical trials, which is partly due to inadequacy of animal models to accurately predict the toxic side-effects of drugs in humans [1,2].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [2]
In the citing paper
“Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR), and it can lead to liver failure and even death.[1][2][3]”
From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [1]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen
Chan, K., Han, X.-D., & Kan, Y. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081082098 · Cited by 770
Incidence of drug-induced hepatic injuries: A French population-based study
Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., Lenoir, C., Lemoine, A., & Hillon, P. (2002) · Hepatology · doi:10.1053/jhep.2002.34857 · Cited by 716
Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver
(1980) · Food and Cosmetics Toxicology · doi:10.1016/0015-6264(80)90206-0 · Cited by 691
Role of CYP2E1 in the Hepatotoxicity of Acetaminophen
Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., & Gonzalez, F. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.12063 · Cited by 656
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver
Maddrey, W. C. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70192-2 · Cited by 646
Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., & Meier, P. J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70224-1 · Cited by 582
Outcome and prognostic markers in severe drug‐induced liver disease†
Björnsson, E., & Olsson, R. (2005) · Hepatology · doi:10.1002/hep.20800 · Cited by 524
Kon, K., Kim, J.-S., Jaeschke, H., & Lemasters, J. J. (2004) · Hepatology · doi:10.1002/hep.20437 · Cited by 494
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426
Acute and clinically relevant drug‐induced liver injury: a population based case‐control study
De Abajo, F. J., Montero, D., Madurga, M., & Rodríguez, L. A. G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02133.x · Cited by 408
Berson, A., De Beco, V., Lettéron, P., Robin, M. A., Moreau, C., Kahwaji, J. E., Verthier, N., Feldmann, G., Fromenty, B., & Pessayre, D. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70590-6 · Cited by 405
Liver transplantation for acute liver failure from drug induced liver injury in the United States
Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W., & Watkins, P. (2004) · Liver Transplantation · doi:10.1002/lt.20204 · Cited by 393
Mitochondria in Steatohepatitis
Pessayre, D., Berson, A., Fromenty, B., & Mansouri, A. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-12929 · Cited by 391
Lindon, J. C., Nicholson, J. K., Holmes, E., Antti, H., Bollard, M. E., Keun, H., Beckonert, O., Ebbels, T. M., Reily, M. D., Robertson, D., et al. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(02)00079-0 · Cited by 385
Nolan, C. M., Goldberg, S. V., & Buskin, S. E. (1999) · JAMA · doi:10.1001/jama.281.11.1014 · Cited by 368
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Alv�n, G., Bechtel, P., Iselius, L., & Gundert-Remy, U. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316090 · Cited by 361
Protective Role of Kupffer Cells in Acetaminophen-Induced Hepatic Injury in Mice
Ju, C., Reilly, T. P., Bourdi, M., Radonovich, M. F., Brady, J. N., George, J. W., & Pohl, L. R. (2002) · Chemical Research in Toxicology · doi:10.1021/tx0255976 · Cited by 360
Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
Maria, V. A., & Victorino, R. M. (1997) · Hepatology · doi:10.1002/hep.510260319 · Cited by 351
Liu, Z.-X., Govindarajan, S., & Kaplowitz, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.053 · Cited by 328
Self-citationRole of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity
Walgren, J. L., Mitchell, M. D., & Thompson, D. C. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935620 · Cited by 322
Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR
Zhang, J., Huang, W., Chua, S. S., Wei, P., & Moore, D. D. (2002) · Science · doi:10.1126/science.1073502 · Cited by 316
Mechanisms of liver cell injury
Kaplowitz, N. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80414-6 · Cited by 311
Self-citationLiver biology and pathobiology
Kaplowitz, N. (2006) · Hepatology · doi:10.1002/hep.20958 · Cited by 305
Self-citationBourdi, M., Masubuchi, Y., Reilly, T. P., Amouzadeh, H. R., Martin, J. L., George, J. W., Shah, A. G., & Pohl, L. R. (2002) · Hepatology · doi:10.1053/jhep.2002.30956 · Cited by 302
UNGO, J. R., JONES, D., ASHKIN, D., HOLLENDER, E. S., BERNSTEIN, D., ALBANESE, A. P., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9711039 · Cited by 292
Vergani, D., Mieli-Vergani, G., Alberti, A., Neuberger, J., Eddleston, A. L. W. F., Davis, M., & Williams, R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198007103030202 · Cited by 285
Hepatobiliary transporters and drug‐induced cholestasis†
Pauli‐Magnus, C., & Meier, P. J. (2006) · Hepatology · doi:10.1002/hep.21359 · Cited by 285
Zhang, H., Cook, J., Nickel, J., Yu, R., Stecker, K., Myers, K., & Dean, N. M. (2000) · Nature Biotechnology · doi:10.1038/78475 · Cited by 268
Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients
Lewis, J. H., Ranard, R. C., Caruso, A., Jackson, L. K., Mullick, F., Ishak, K. G., Seeff, L. B., & Zimmerman, H. J. (1989) · Hepatology · doi:10.1002/hep.1840090504 · Cited by 266
Drug-Induced Liver Disorders: Implications for Drug Development and Regulation
Kaplowitz, N. (2001) · Drug Safety · doi:10.2165/00002018-200124070-00001 · Cited by 260
Self-citationLarrey, D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80417-1 · Cited by 253
Mitochondrial abnormalities—A link to idiosyncratic drug hepatotoxicity?
Boelsterli, U. A., & Lim, P. L. K. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.013 · Cited by 232
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
Wong, W.-M., Wu, P.-C., Yuen, M.-F., Cheng, C.-C., Yew, W.-W., Wong, P.-C., Tam, C.-M., Leung, C.-C., & Lai, C.-L. (2000) · Hepatology · doi:10.1002/hep.510310129 · Cited by 231
A pivotal involvement of IFN‐' in the pathogenesis of acetaminophen‐induced acute liver injury
Ishida, Y., Kondo, T., Ohshima, T., Fujiwara, H., Iwakura, Y., & Mukaida, N. (2002) · The FASEB Journal · doi:10.1096/fj.02-0046com · Cited by 226
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S -transferase Pi
Henderson, C. J., Wolf, C. R., Kitteringham, N., Powell, H., Otto, D., & Park, B. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220176997 · Cited by 222
Aithal, G. P., Ramsay, L., Daly, A. K., Sonchit, N., Leathart, J. B. S., Alexander, G., Kenna, G. J., Caldwell, J., & Day, C. P. (2004) · Hepatology · doi:10.1002/hep.20205 · Cited by 216
Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Fountain, F. F., Tolley, E., Chrisman, C. R., & Self, T. H. (2005) · Chest · doi:10.1378/chest.128.1.116 · Cited by 209
(2025) · Seminars in Liver Disease · doi:10.1055/s-00000069 · Cited by 209
Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice
Goldring, C. E. P., Kitteringham, N. R., Elsby, R., Randle, L. E., Clement, Y. N., Williams, D. P., McMahon, M., Hayes, J. D., Itoh, K., Yamamoto, M., et al. (2004) · Hepatology · doi:10.1002/hep.20183 · Cited by 207
The natural history of histologically proved drug induced liver disease
Aithal, P. G., & Day, C. P. (1999) · Gut · doi:10.1136/gut.44.5.731 · Cited by 202
Isoniazid-associated Hepatitis Deaths: A Review of Available Information
Snider, D. E., & Caras, G. J. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.2_pt_1.494 · Cited by 199
Hepatic Findings in Long-Term Clinical Trials of Ximelagatran
Lee, W. M., Larrey, D., Olsson, R., Lewis, J. H., Keisu, M., Auclert, L., & Sheth, S. (2005) · Drug Safety · doi:10.2165/00002018-200528040-00006 · Cited by 189
Spagnuolo, M., Iorio, R., Vegnente, A., & Guarino, A. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8780577 · Cited by 189
Degott, C., Feldmann, G., Larrey, D., Durand-Schneider, A.-M., Grange, D., Machayekhi, J.-P., Moreau, A., Potet, F., & Benhamou, J.-P. (1992) · Hepatology · doi:10.1002/hep.1840150212 · Cited by 187
Nagai, H., Matsumaru, K., Feng, G., & Kaplowitz, N. (2002) · Hepatology · doi:10.1053/jhep.2002.33995 · Cited by 186
Self-citationTroglitazone-induced liver failure: a case study
Graham, D. J., Green, L., Senior, J. R., & Nourjah, P. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01529-2 · Cited by 186
Zimmerman, H. J. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70097-0 · Cited by 186
Effect of l -carnitine treatment for valproate-induced hepatotoxicity
Bohan, T. P., Helton, E., McDonald, I., König, S., Gazitt, S., Sugimoto, T., Scheffner, D., Cusmano, L., Li, S., & Koch, G. (2001) · Neurology · doi:10.1212/wnl.56.10.1405 · Cited by 184
Risk of Acute Liver Injury Associated With the Combination of Amoxicillin and Clavulanic Acid
Rodríguez, L. A. G. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440110099013 · Cited by 181
Role of MRP2 and GSH in intrahepatic cycling of toxins
Dietrich, C. (2001) · Toxicology · doi:10.1016/s0300-483x(01)00459-0 · Cited by 177
Park, D. R., Thomsen, A. R., Frevert, C. W., Pham, U., Skerrett, S. J., Kiener, P. A., & Liles, W. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6209 · Cited by 176
Hepatitis induced by Kava (Piper methysticum rhizoma)
Stickel, F., Baumüller, H.-M., Seitz, K., Vasilakis, D., Seitz, G., Seitz, H. K., & Schuppan, D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00175-2 · Cited by 175
Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00014-6 · Cited by 174
Acute hepatitis induced by greater celandine (Chelidonium majus)
Benninger, J., Schneider, H. T., Schuppan, D., Kirchner, T., & Hahn, E. G. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70410-5 · Cited by 173
Iverson, S. L., & Uetrecht, J. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002029 · Cited by 171
Lucena, M. I., Andrade, R. J., Fernández, M. C., Pachkoria, K., Pelaez, G., Durán, J. A., Villar, M., Rodrigo, L., Romero‐Gomez, M., Planas, R., et al. (2006) · Hepatology · doi:10.1002/hep.21324 · Cited by 166
A prospective study of the causes of notably raised aspartate aminotransferase of liver origin
Whitehead, M. W., Hawkes, N. D., Hainsworth, I., & Kingham, J. G. C. (1999) · Gut · doi:10.1136/gut.45.1.129 · Cited by 166
Idiosyncratic Liver Injury: Challenges and Approaches
Watkins, P. B. (2005) · Toxicologic Pathology · doi:10.1080/01926230590888306 · Cited by 166
Impaired oxidation of debrisoquine in patients with perhexiline liver injury.
Morgan, M. Y., Reshef, R., Shah, R. R., Oates, N. S., Smith, R. L., & Sherlock, S. (1984) · Gut · doi:10.1136/gut.25.10.1057 · Cited by 163
Incidence of drug-induced liver injury in medical inpatients
Meier, Y., Cavallaro, M., Roos, M., Pauli-Magnus, C., Folkers, G., Meier, P. J., & Fattinger, K. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0888-z · Cited by 158
Clinical Hepatology: Profile of An Urban, Hospital–Based Practic
Byron, D., & Minuk, G. Y. (1996) · Hepatology · doi:10.1002/hep.510240410 · Cited by 156
Masubuchi, Y., Bourdi, M., Reilly, T. P., Graf, M. L. M., George, J. W., & Pohl, L. R. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00572-2 · Cited by 155
Andrade, R. J., Lucena, M. I., Alonso, A. O., García‐Cortés, M., García-Ruiz, E., Benitez, R. A., Fernández, C. M. A., Peláez, G. I. C., Romero, M., Corpas, R., et al. (2004) · Hepatology · doi:10.1002/hep.20215 · Cited by 154
Hohlbaum, A. M., Gregory, M. S., Ju, S., & Marshak‐Rothstein, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6217 · Cited by 149
A Protective Role for Cyclooxygenase-2 in Drug-Induced Liver Injury in Mice
Reilly, T. P., Brady, J. N., Marchick, M. R., Bourdi, M., George, J. W., Radonovich, M. F., Pise-Masison, C. A., & Pohl, L. R. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0155505 · Cited by 145
Matsumaru, K., Ji, C., & Kaplowitz, N. (2003) · Hepatology · doi:10.1053/jhep.2003.50230 · Cited by 143
Self-citationEthanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults
Thummel, K. E., Slattery, J. T., Ro, H., Chien, J. Y., Nelson, S. D., Lown, K. E., & Watkins, P. B. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106574 · Cited by 142
Acetaminophen hepatoxicity: What do we know, what don’t we know, and what do we do next?†
Kaplowitz, N. (2004) · Hepatology · doi:10.1002/hep.20312 · Cited by 138
Self-citationTroglitazone and liver injury: In search of answers†
Chojkier, M. (2005) · Hepatology · doi:10.1002/hep.20567 · Cited by 137
Liver Enzyme Monitoring in Patients Treated With Troglitazone
Graham, D. J. (2001) · JAMA · doi:10.1001/jama.286.7.831 · Cited by 136
Shayiq, R. M., Roberts, D. W., Rothstein, K. D., SNAWDER, J. E., Benson, W., Ma, X., & Black, M. (1999) · Hepatology · doi:10.1002/hep.510290241 · Cited by 135
Drug-induced liver injury network (DILIN)
Hoofnagle, J. H. (2004) · Hepatology · doi:10.1002/hep.1840400403 · Cited by 134
Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid
Rodriguez, L. A. G. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.12.1327 · Cited by 132
The Danger Hypothesis Applied to Idiosyncratic Drug Reactions
Li, J., & Uetrecht, J. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_18 · Cited by 130
Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis
Robin, M., Roy, M. L., Descatoire, V., & Pessayre, D. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)82329-x · Cited by 129
Exaggerated Hepatic Injury Due to Acetaminophen Challenge in Mice Lacking C-C Chemokine Receptor 2
Hogaboam, C. M., Bone‐Larson, C. L., Steinhauser, M. L., Matsukawa, A., Gosling, J., Boring, L. F., Charo, I. F., Simpson, K. J., Lukacs, N. W., & Kunkel, S. L. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64995-4 · Cited by 127
Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment
van Hest, R., Baars, H., Kik, S. V., van Gerven, P., Trompenaars, M. E., Kalisvaart, N. A., Keizer, S. T., Borgdorff, M. W., Mensen, M., & Cobelens, F. G. J. (2004) · Clinical Infectious Diseases · doi:10.1086/422645 · Cited by 125
Accuracy of hepatic adverse drug reaction reporting in one English health region
Aithal, G. P., Rawlins, M. D., & Day, C. P. (1999) · BMJ · doi:10.1136/bmj.319.7224.1541 · Cited by 124
Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden
Björnsson, E., Jerlstad, P., Bergqvist, A., & Olsson, R. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510023846 · Cited by 123
DATABASE DEVELOPMENT IN TOXICOGENOMICS: ISSUES AND EFFORTS
Mattes, W. B., Pettit, S. D., Sansone, S., Bushel, P. R., & Waters, M. D. (2004) · Environmental Health Perspectives · doi:10.1289/ehp.6697 · Cited by 123
Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
Simon, T. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104944 · Cited by 122
Causality Assessment Versus Guilt–By–Association in Drug Hepatotoxicity
Kaplowitz, N. (2001) · Hepatology · doi:10.1053/jhep.2001.21083 · Cited by 122
Self-citationA double-blinded, randomized trial of hydrocortisone in acute hepatic failure
Rakela, J. L., Mosley, J. W., Edwards, V. M., Govindarajan, S., Alpert, E., & The Acute Hepatic Failure Study Group (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01307513 · Cited by 120
Olsson, I., Larsson, K., Palmgren, R., & Bjellqvist, B. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200211)2:11<1479::aid-prot1479>3.0.co;2-a · Cited by 120
Hepatotoxicity of Psychotropic Drugs
Selim, K., & Kaplowitz, N. (1999) · Hepatology · doi:10.1002/hep.510290535 · Cited by 119
Self-citationNjoku, D. B., Greenberg, R. S., Bourdi, M., Borkowf, C. B., Dake, E. M., Martin, J. L., & Pohl, L. R. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200202000-00003 · Cited by 114
Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury
Maria, V. A. J., & Victorino, R. M. M. (1997) · Gut · doi:10.1136/gut.41.4.534 · Cited by 111
Neff, G. W., Reddy, K. R., Durazo, F. A., Meyer, D., Marrero, R., & Kaplowitz, N. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.06.028 · Cited by 110
Self-citationEffects of Troglitazone on HepG2 Viability and Mitochondrial Function
Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanan, P. K., Kurali, E., Hart, T. K., Thomas, H. C., & Schwartz, L. W. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.131 · Cited by 109
Novel CXCR2‐dependent liver regenerative qualities of ELR‐containing CXC chemokines
Hogaboam, C. M., Bone‐Larson, C. L., Steinhauser, M. L., Lukacs, N. W., Colletti, L. M., Simpson, K. J., Strieter, R. M., & Kunkel, S. L. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1565 · Cited by 107
Clinical Perspectives on Xenobiotic‐Induced Hepatotoxicity
Gunawan, B. K., & Kaplowitz, N. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120034148 · Cited by 107
Self-citationKaplowitz, N. (2002) · CRC Press eBooks · doi:10.1201/b15279 · Cited by 102
Self-citationDefining patient risks from expanded preventive therapies
Tolman, K. G. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00946-2 · Cited by 98
Hepatic Injury in 12 Patients Taking the Herbal Weight Loss Aids Chaso or Onshido
Adachi, M., Saito, H., Kobayashi, H., Horie, Y., Kato, S., Yoshioka, M., & Ishii, H. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-6-200309160-00012 · Cited by 97
Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
Kornbrust, D. J., MacDonald, J. S., Peter, C. P., Duchai, D. M., Stubbs, R. J., Germershausen, J. I., & Alberts, A. W. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23730-2 · Cited by 96
Trovafloxacin-Induced Acute Hepatitis
Lucena, M. I., Andrade, R. J., Rodrigo, L., Salmerón, J., Alvarez, A., Lopez-Garrido, M. J., Camargo, R., & Alcántara, R. (2000) · Clinical Infectious Diseases · doi:10.1086/313680 · Cited by 95
Role of reactive metabolites in drug-induced hepatitis
Pessayre, D. (1995) · Journal of Hepatology · doi:10.1016/s0168-8278(21)80002-1 · Cited by 86
Clinical characteristics and prognostic markers in disulfiram-induced liver injury
Bjornsson, E. S., Nordlinder, H., & Olsson, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.016 · Cited by 83
Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral Therapy
Bonfanti, P., Landonio, S., Ricci, E. D., Martinelli, C. V., Fortuna, P., Faggion, I., & Quirino, T. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200107010-00017 · Cited by 82
Role of Viral Infections in the Induction of Adverse Drug Reactions
Levy, M. (1997) · Drug Safety · doi:10.2165/00002018-199716010-00001 · Cited by 81
Immune mechanisms in tienilic acid associated hepatotoxicity.
Neuberger, J., & Williams, R. L. (1989) · Gut · doi:10.1136/gut.30.4.515 · Cited by 80
The danger hypothesis applied to idiosyncratic drug reactions
Séguin, B., & Uetrecht, J. (2003) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200308000-00001 · Cited by 80
Bone‐Larson, C. L., Hogaboam, C. M., Evanhoff, H., Strieter, R. M., & Kunkel, S. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7077 · Cited by 78
Ulrich, R. G., Rockett, J. C., Gibson, G. G., & Pettit, S. D. (2004) · Environmental Health Perspectives · doi:10.1289/ehp.6675 · Cited by 78
Acuña, G., Foernzler, D., Leong, D. U., Rabbia, M. A., Smit, R., Dorflinger, E. E., Gasser, R., Hoh, J. J., Ott, J., Borroni, E., et al. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500123 · Cited by 77
Lakehal, F., Dansette, P. M., Becquemont, L., Lasnier, E., Delelo, R., Balladur, P., Poupon, R. Y., Beaune, P. H., & Housset, C. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002435 · Cited by 76
The rational use of potentially hepatotoxic medications in patients with underlying liver disease
Lewis, J. H. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.2.159 · Cited by 73
Blackard, W. G., Sood, G., Crowe, D. R., & Fallon, M. B. (1998) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199801000-00015 · Cited by 72
Rodríguez, L. A. G., Ruigómez, A., & Jick, H. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03747.x · Cited by 71
Severe Hepatotoxicity Associated with Troglitazone
Herrine, S. K., & Choudhary, C. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-2-199901190-00021 · Cited by 68
Takikawa, H. (2003) · Hepatology Research · doi:10.1016/s1386-6346(03)00232-8 · Cited by 68
Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization.
Chien, J. Y., Thummel, K. E., & Slattery, J. T. (1997) · PubMed · Cited by 66
Erythromycin‐Associated Cholestatic Hepatitis
Derby, L. E., Jick, H., Henry, D. A., & Dean, A. D. (1993) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb137625.x · Cited by 64
Menon, K. V. N., Angulo, P., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02372-3 · Cited by 62
Inflammatory mechanisms in childhood asthma
Warner, Marguet, Rao, Roche, & Pohunek (1998) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1998.028s5071.x · Cited by 60
Hogaboam, C. M., Simpson, K. J., Chensue, S. W., Steinhauser, M. L., Lukacs, N. W., Gauldie, J., Strieter, R. M., & Kunkel, S. L. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300858 · Cited by 59
Gutthann, S. P., & Garcia Rodeíguez, L. A. (1993) · Epidemiology · doi:10.1097/00001648-199311000-00004 · Cited by 58
Liver biopsy in elevated liver functions tests? An old question revisited
Bianchi, L. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00155-6 · Cited by 58
Severe Jaundice in Sweden in the New Millennium: Causes, Investigations, Treatment and Prognosis
Björnsson, E., Ismael, S., Nejdet, S., & Kilander, A. F. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310000492 · Cited by 57
Pessayre, D., Haouzi, D., Fau, D., Robin, M. A., Mansouri, A., & Berson, A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80360-2 · Cited by 56
Lipopolysaccharide-binding protein modulates acetaminophen-induced liver injury in mice
Su, G. L., Gong, K. Q., Fan, M. H., Kelley, W. M., Hsieh, J. K., Sun, J. M., Hemmila, M. R., Arbabi, S., Remick, D. G., & Wang, S. C. (2005) · Hepatology · doi:10.1002/hep.20533 · Cited by 55
Acute liver injury associated with the use of ebrotidine, a new H 2 -receptor antagonist
Andrade, R. J., Lucena, M. I., Martín-Vivaldi, R., Fernández‐Santaella, M. C., Nogueras, F., Peláez, G. I. C., Gómez‐Outes, A., García-Escaño, M. D., Bellot, V., Hervás, A., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80343-2 · Cited by 55
Drug associated hepatic reactions in New Zealand: 21 years experience.
Pillans, P. I. (1996) · PubMed · Cited by 53
Horsmans, Y., Desager, J. P., & Harvengt, C. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00840.x · Cited by 49
Lloyd, S., Hayden, M. J., Sakai, Y., Fackett, A., Silber, P. M., Hewitt, N. J., & Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00054-6 · Cited by 46
WATANABE, M. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.08.005 · Cited by 44
Protective Effect of rhIL-11 in a Murine Model of Acetaminophen-Induced Hepatotoxicity
Trepicchio, W. L., Bozza, M., Bouchard, P. R., & Dorner, A. J. (2001) · Toxicologic Pathology · doi:10.1080/019262301317052521 · Cited by 43
Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.
La, O., Jacob, L., Gm, C., Tp, L., Ben-Zvi, J. S., Donelson, S. S., & Felton, C. P. (1995) · PubMed · Cited by 41
A Study of Compliance With FDA Recommendations for Pemoline (Cylert®)
Willy, M. E., Manda, B., Shatin, D., Drinkard, C. R., & Graham, D. J. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00009 · Cited by 39
Toxic effect of troglitazone on cultured rat hepatocytes
Toyoda, Y., Tsuchida, A., Iwami, E., & Miwa, I. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)00985-7 · Cited by 39
Protein expression analysis of drug-mediated hepatotoxicity in the Sprague-Dawley rat
Man, W. J., White, I. R., Bryant, D. K., Bugelski, P. J., Camilleri, P., Cutler, P., Heald, G., Lord, P. G., Wood, J., & Kramer, K. (2002) · PROTEOMICS · Cited by 37
Case Report: Chronic Liver Injury Related to Use of Bentazepam
Andrade, R. J., Lucena, M. I., Aguilar, J. M. V., Lazo, M., Camargo, R., Moreno, P., García-Escaño, M. D., Márquez, A., Alcántara, R., & Alcaín, G. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005520523502 · Cited by 36
Rf, B., Ke, H., Rw, H., & Ae, M. (1990) · PubMed · Cited by 35
Halothane-lnduced Hepatic Disease
Touloukian, J., & Kaplowitz, N. (1981) · Seminars in Liver Disease · doi:10.1055/s-2008-1040726 · Cited by 34
Self-citationHorsmans, Y., Lannes, D., Pessayre, D., & Larrey, D. G. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80620-8 · Cited by 33
Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS)
Hüster, D., Schubert, C., Berr, F., Mössner, J., & Caca, K. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00177-0 · Cited by 32
Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice
Tinel, M., Berson, A., Vadrot, N., Descatoire, V., Grodet, A., Feldmann, G., Thénot, J. P., & Pessayre, D. (2004) · Hepatology · doi:10.1002/hep.20094 · Cited by 29
Immunological investigation in hepatic drug reactions.
Maria, V. A. J., & Victorino, R. M. M. (1998) · PubMed · Cited by 18
Drug Induced Liver Injury Network (DILIN) Prospective Study
Chalasani, N., Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Davern, T. J., Serrano, J., & Rochon, J. (2006) · The American Journal of Gastroenterology · doi:10.14309/00000434-200609001-00375 · Cited by 10
Nefazodone in community use: the results of prescription-event monitoring
Mackay, F. J., Pearce, G. L., Freemantle, S. N., & Mann, R. D. (1999) · Pharmacoepidemiology and Drug Safety · doi:10.1002/(sici)1099-1557(199907)8:4<275::aid-pds427>3.0.co;2-d · Cited by 5
686 Comparison of two clinical scales in the causality assessment of drug induced liver disease
García‐Cortés, M., Pachkoria, K., Lucena, M. I., Andrade, R., Camargo, R., Alcántara, R., & Hidalgo, R. (2006) · Journal of Hepatology · doi:10.1016/s0168-8278(06)80686-0 · Cited by 2
(2005) · PubMed
Research works printed but not linked: 3
- Nelson, S. D. & Bruschi, S. A. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 287–325 (Marcel Dekker, New York, 2003).
- Chien, J. Y., Thummel, K. E. & Slattery, J. T. Pharmakinetic consequence of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165–1175 (1997).
- Liu, Z. -X. & Kaplowitz, N. in Clinics in Liver Disease 6, 467–486 (Elsevier, 2002).
Cited by
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citation
Metadata
- Authors
- Kaplowitz, N.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kaplowitz, Neil
- ORCID
- Kaplowitz, Neil
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-06
- Volume
- 4
- Issue
- 6
- Pages
- 489-499
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2017783406
- Cited by
- 1,054
- References
- 155
- Citations by year
- 2026: 29 · 2025: 35 · 2024: 35 · 2023: 44 · 2022: 31 · 2021: 49 · 2020: 45 · 2019: 48 · 2018: 54 · 2017: 66 · 2016: 72 · 2015: 55 · 2014: 64 · 2013: 57 · 2012: 52
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, troglitazone, preclinical toxicology, hepatotoxicity prediction, pharmacovigilance, acetaminophen hepatotoxicity, innate immune system, cell death pathways, drug withdrawal, post-marketing surveillance
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Liver, Liver Diseases, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.